134 related articles for article (PubMed ID: 31757375)
1. Distribution of NRG1 Gene Fusions in a Large Population of Chinese Patients with NSCLC.
Ke H; Shen W; Hu A; Ou Q; Lu S
J Thorac Oncol; 2019 Dec; 14(12):e263-e266. PubMed ID: 31757375
[No Abstract] [Full Text] [Related]
2. The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring
Kim DW; Schram AM; Hollebecque A; Nishino K; Macarulla T; Rha SY; Duruisseaux M; Liu SV; Al Hallak MN; Umemoto K; Wesseler C; Cleary JM; Springfeld C; Neuzillet C; Joe A; Jauhari S; Ford J; Goto K
Future Oncol; 2024; 20(16):1057-1067. PubMed ID: 38348690
[TBL] [Abstract][Full Text] [Related]
3. VAMP2-NRG1 Fusion Gene is a Novel Oncogenic Driver of Non-Small-Cell Lung Adenocarcinoma.
Jung Y; Yong S; Kim P; Lee HY; Jung Y; Keum J; Lee S; Kim J; Kim J
J Thorac Oncol; 2015 Jul; 10(7):1107-11. PubMed ID: 26134228
[TBL] [Abstract][Full Text] [Related]
4. Detection of Novel NRG1, EGFR, and MET Fusions in Lung Adenocarcinomas in the Chinese Population.
Pan Y; Zhang Y; Ye T; Zhao Y; Gao Z; Yuan H; Zheng D; Zheng S; Li H; Li Y; Jin Y; Sun Y; Chen H
J Thorac Oncol; 2019 Nov; 14(11):2003-2008. PubMed ID: 31382039
[TBL] [Abstract][Full Text] [Related]
5. NRG1 and NRG2 fusions in non-small cell lung cancer (NSCLC): seven years between lights and shadows.
Trombetta D; Sparaneo A; Fabrizio FP; Di Micco CM; Rossi A; Muscarella LA
Expert Opin Ther Targets; 2021 Oct; 25(10):865-875. PubMed ID: 34706602
[TBL] [Abstract][Full Text] [Related]
6. Durable Response to Afatinib in Lung Adenocarcinoma Harboring NRG1 Gene Fusions.
Gay ND; Wang Y; Beadling C; Warrick A; Neff T; Corless CL; Tolba K
J Thorac Oncol; 2017 Aug; 12(8):e107-e110. PubMed ID: 28502724
[No Abstract] [Full Text] [Related]
7. Targeting Neuregulin 1 (NRG1): A Novel Biomarker for Non-Small-Cell Lung Cancer.
Fang C; Kang B; Zhao P; Ran J; Wang L; Zhao L; Luo H; Tao L
J Environ Pathol Toxicol Oncol; 2021; 40(4):61-72. PubMed ID: 34936301
[TBL] [Abstract][Full Text] [Related]
8. Detection of NRG1 Gene Fusions in Solid Tumors.
Jonna S; Feldman RA; Swensen J; Gatalica Z; Korn WM; Borghaei H; Ma PC; Nieva JJ; Spira AI; Vanderwalde AM; Wozniak AJ; Kim ES; Liu SV
Clin Cancer Res; 2019 Aug; 25(16):4966-4972. PubMed ID: 30988082
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics and sequence complexity of anaplastic lymphoma kinase gene fusions in Chinese lung cancer patients.
Tian HX; Zhang XC; Yang JJ; Guo WB; Chen ZH; Wang Z; Wu YL
Lung Cancer; 2017 Dec; 114():90-95. PubMed ID: 29173772
[TBL] [Abstract][Full Text] [Related]
10. NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents.
Laskin J; Liu SV; Tolba K; Heining C; Schlenk RF; Cheema P; Cadranel J; Jones MR; Drilon A; Cseh A; Gyorffy S; Solca F; Duruisseaux M
Ann Oncol; 2020 Dec; 31(12):1693-1703. PubMed ID: 32916265
[TBL] [Abstract][Full Text] [Related]
11. RNA Sequencing Identifies Novel NRG1 Fusions in Solid Tumors that Lack Co-Occurring Oncogenic Drivers.
Severson E; Achyut BR; Nesline M; Pabla S; Previs RA; Kannan G; Chenn A; Zhang S; Klein R; Conroy J; Sausen M; Sathyan P; Saini KS; Ghosh A; Jensen TJ; Reddy P; Ramkissoon SH
J Mol Diagn; 2023 Jul; 25(7):454-466. PubMed ID: 37164276
[TBL] [Abstract][Full Text] [Related]
12. Multidriver mutation analysis in pulmonary mucinous adenocarcinoma in Taiwan: identification of a rare CD74-NRG1 translocation case.
Gow CH; Wu SG; Chang YL; Shih JY
Med Oncol; 2014 Jul; 31(7):34. PubMed ID: 24913807
[TBL] [Abstract][Full Text] [Related]
13. Identification of tumors with NRG1 rearrangement, including a novel putative pathogenic UNC5D-NRG1 gene fusion in prostate cancer by data-drilling a de-identified tumor database.
Ptáková N; Martínek P; Holubec L; Janovský V; Vančurová J; Grossmann P; Navarro PA; Rodriguez Moreno JF; Alaghehbandan R; Hes O; Májek O; Pešek M; Michal M; Ondič O
Genes Chromosomes Cancer; 2021 Jul; 60(7):474-481. PubMed ID: 33583086
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung.
Shin DH; Lee D; Hong DW; Hong SH; Hwang JA; Lee BI; You HJ; Lee GK; Kim IH; Lee YS; Han JY
Oncotarget; 2016 Oct; 7(43):69450-69465. PubMed ID: 27626312
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.
Cadranel J; Liu SV; Duruisseaux M; Branden E; Goto Y; Weinberg BA; Heining C; Schlenk RF; Cheema P; Jones MR; Drilon A; Trombetta D; Muscarella LA; Tolba K; Gounant V; Cseh A; Solca F; Laskin JJ; Renouf DJ
Oncologist; 2021 Jan; 26(1):7-16. PubMed ID: 32852072
[TBL] [Abstract][Full Text] [Related]
16. KIF5B-RET fusions in Chinese patients with non-small cell lung cancer.
Cai W; Su C; Li X; Fan L; Zheng L; Fei K; Zhou C
Cancer; 2013 Apr; 119(8):1486-94. PubMed ID: 23378251
[TBL] [Abstract][Full Text] [Related]
17. Molecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
Zhou X; Shou J; Sheng J; Xu C; Ren S; Cai X; Chu Q; Wang W; Zhen Q; Zhou Y; Li W; Pan H; Li H; Sun T; Cheng H; Wang H; Lou F; Rao C; Cao S; Pan H; Fang Y
Cancer Sci; 2019 Oct; 110(10):3382-3390. PubMed ID: 31444835
[TBL] [Abstract][Full Text] [Related]
18. Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.
Shin DH; Jo JY; Han JY
Mol Cancer Ther; 2018 Sep; 17(9):2024-2033. PubMed ID: 29959202
[TBL] [Abstract][Full Text] [Related]
19. Plain language summary of NRG1 fusions in cancer: current knowledge and treatment with afatinib and other drugs.
Liu SV
Future Oncol; 2022 Aug; 18(26):2865-2870. PubMed ID: 35876504
[TBL] [Abstract][Full Text] [Related]
20. ALK and NRG1 Fusions Coexist in a Patient with Signet Ring Cell Lung Adenocarcinoma.
Muscarella LA; Trombetta D; Fabrizio FP; Scarpa A; Fazio VM; Maiello E; Rossi A; Graziano P
J Thorac Oncol; 2017 Oct; 12(10):e161-e163. PubMed ID: 28939148
[No Abstract] [Full Text] [Related]
[Next] [New Search]
